{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:21:46Z","timestamp":1791397306985,"version":"4.3.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS100779"],"award-info":[{"award-number":["R01 NS100779"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Krabbe disease (KD) and metachromatic leukodystrophy (MLD) are caused by accumulation of the glycolipids galactosylceramide (GalCer) and sulfatide and their toxic metabolites psychosine and lysosulfatide, respectively. We discovered a potent and selective small molecule inhibitor (S202) of ceramide galactosyltransferase (CGT), the key enzyme for GalCer biosynthesis, and characterized its use as substrate reduction therapy (SRT). Treating a KD mouse model with S202 dose-dependently reduced GalCer and psychosine in the central (CNS) and peripheral (PNS) nervous systems and significantly increased lifespan. Similarly, treating an MLD mouse model decreased sulfatides and lysosulfatide levels. Interestingly, lower doses of S202 partially inhibited CGT and selectively reduced synthesis of non-hydroxylated forms of GalCer and sulfatide, which appear to be the primary source of psychosine and lysosulfatide. Higher doses of S202 more completely inhibited CGT and reduced the levels of both non-hydroxylated and hydroxylated forms of GalCer and sulfatide. Despite the significant benefits observed in murine models of KD and MLD, chronic CGT inhibition negatively impacted both the CNS and PNS of wild-type mice. Therefore, further studies are necessary to elucidate the full therapeutic potential of CGT inhibition.<\/jats:p>","DOI":"10.1038\/s41598-021-93601-1","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T06:03:36Z","timestamp":1626242616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Substrate reduction therapy for Krabbe disease and metachromatic leukodystrophy using a novel ceramide galactosyltransferase inhibitor"],"prefix":"10.1038","volume":"11","author":[{"given":"Michael C.","family":"Babcock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina R.","family":"Mikulka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Chandriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundeep","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemanth R.","family":"Nelvagal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Giaramita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan K.","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuntian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh C.","family":"Woloszynek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shripad","family":"Bhagwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett E.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"93601_CR1","unstructured":"Wenger D. A., Escolar, M, L, Luzi, P., Rafi, M. A. in The Online Metabolic and Molecular Bases of Inherited Disease (eds. Valle, D. L, Antonarakis, S., Ballabio, A., Beaudet, A. L., Mitchell, G. A.) (McGraw-Hill Education, 2019)."},{"key":"93601_CR2","unstructured":"V. Gieselmann, K.-M. Ingeborg, in The Online Metabolic and Molecular Bases of Inherited Disease (eds. Valle, D. L, Antonarakis, S., Ballabio, A., Beaudet, A. L., Mitchell, G. A.) (McGraw-Hill Education, 2019)."},{"key":"93601_CR3","doi-asserted-by":"publisher","first-page":"20097","DOI":"10.1073\/pnas.1912108116","volume":"116","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target. Proc. Natl. Acad. Sci. USA 116, 20097\u201320103 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"93601_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1042\/bj3170589","volume":"317","author":"P van der Bijl","year":"1996","unstructured":"van der Bijl, P., Strous, G. J., Lopes-Cardozo, M., Thomas-Oates, J. & van Meer, G. Synthesis of non-hydroxy-galactosylceramides and galactosyldiglycerides by hydroxy-ceramide galactosyltransferase. Biochem. J. 317, 589\u2013597 (1996).","journal-title":"Biochem. J."},{"key":"93601_CR5","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1046\/j.1471-4159.1995.65052267.x","volume":"65","author":"N Schaeren-Wiemers","year":"2002","unstructured":"Schaeren-Wiemers, N., van der Bijl, P. & Schwab, M. E. The UDP-galactose: Ceramide galactosyltransferase: Expression pattern in oligodendrocytes and schwann cells during myelination and substrate preference for hydroxyceramide. J. Neurochem. 65, 2267\u20132278 (2002).","journal-title":"J. Neurochem."},{"key":"93601_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1194\/jlr.M700400-JLR200","volume":"49","author":"EN Maldonado","year":"2008","unstructured":"Maldonado, E. N., Alderson, N. L., Monje, P. V., Wood, P. M. & Hama, H. FA2H is responsible for the formation of 2-hydroxy galactolipids in peripheral nervous system myelin. J. Lipid Res. 49, 153\u2013161 (2008).","journal-title":"J. Lipid Res."},{"key":"93601_CR7","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1046\/j.1471-4159.1998.70010308.x","volume":"70","author":"A Bosio","year":"2002","unstructured":"Bosio, A., Binczek, E., Haupt, W. F. & Stoffel, W. Composition and biophysical properties of myelin lipid define the neurological defects in galactocerebroside- and sulfatide-deficient mice. J. Neurochem. 70, 308\u2013315 (2002).","journal-title":"J. Neurochem."},{"key":"93601_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jns.2003.09.004","volume":"217","author":"WF Haupt","year":"2004","unstructured":"Haupt, W. F. & Stoffel, W. Nerve conduction velocity measurements reveal the functional deficit in ceramide galactosyl transferase-deficient (cgt\u2212\/\u2212) mice. J. Neurol. Sci. 217, 83\u201388 (2004).","journal-title":"J. Neurol. Sci."},{"key":"93601_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/(SICI)1097-4547(19981201)54:5<613::AID-JNR6>3.0.CO;2-V","volume":"54","author":"T Coetzee","year":"1998","unstructured":"Coetzee, T., Dupree, J. L. & Popko, B. Demyelination and altered expression of myelin-associated glycoprotein isoforms in the central nervous system of galactolipid-deficient mice. J. Neurosci. Res. 54, 613\u2013622 (1998).","journal-title":"J. Neurosci. Res."},{"key":"93601_CR10","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0006-3495(02)75451-9","volume":"82","author":"K Graf","year":"2002","unstructured":"Graf, K., Baltes, H., Ahrens, H., Helm, C. A. & Husted, C. A. Structure of hydroxylated galactocerebrosides from myelin at the air-water interface. Biophys. J . 82, 896\u2013907 (2002).","journal-title":"Biophys. J ."},{"key":"93601_CR11","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S0006-3495(99)76891-8","volume":"77","author":"KM Koshy","year":"1999","unstructured":"Koshy, K. M., Wang, J. & Boggs, J. M. Divalent cation-mediated interaction between cerebroside sulfate and cerebrosides: An investigation of the effect of structural variations of lipids by electrospray ionization mass spectrometry. Biophys. J . 77, 306\u2013318 (1999).","journal-title":"Biophys. J ."},{"key":"93601_CR12","doi-asserted-by":"publisher","first-page":"9741","DOI":"10.1523\/JNEUROSCI.0458-08.2008","volume":"28","author":"I Zoller","year":"2008","unstructured":"Zoller, I. et al. Absence of 2-hydroxylated sphingolipids is compatible with normal neural development but causes late-onset axon and myelin sheath degeneration. J. Neurosci. 28, 9741\u20139754 (2008).","journal-title":"J. Neurosci."},{"key":"93601_CR13","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/glia.21172","volume":"59","author":"KA Potter","year":"2011","unstructured":"Potter, K. A. et al. Central nervous system dysfunction in a mouse model of FA2H deficiency. Glia 59, 1009\u20131021 (2011).","journal-title":"Glia"},{"key":"93601_CR14","doi-asserted-by":"publisher","first-page":"E1251","DOI":"10.1002\/humu.21205","volume":"31","author":"KJ Dick","year":"2010","unstructured":"Dick, K. J. et al. Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35). Hum. Mutat. 31, E1251\u2013E1260 (2010).","journal-title":"Hum. Mutat."},{"key":"93601_CR15","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1021\/acsmedchemlett.0c00120","volume":"11","author":"S Thurairatnam","year":"2020","unstructured":"Thurairatnam, S. et al. Brain penetrable inhibitors of ceramide galactosyltransferase for the treatment of lysosomal storage disorders. ACS Med. Chem. Lett. 11, 2010\u20132016 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"93601_CR16","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3390\/ijms17071065","volume":"17","author":"M Coutinho","year":"2016","unstructured":"Coutinho, M., Santos, J. & Alves, S. Less is more: Substrate reduction therapy for lysosomal storage disorders. IJMS 17, 1065 (2016).","journal-title":"IJMS"},{"key":"93601_CR17","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/ajh.24877","volume":"92","author":"PK Mistry","year":"2017","unstructured":"Mistry, P. K. et al. Outcomes after 18 months of eliglustat therapy in treatment-na\u00efve adults with Gaucher disease type 1: The phase 3 ENGAGE trial. Am. J. Hematol. 92, 1170\u20131176 (2017).","journal-title":"Am. J. Hematol."},{"key":"93601_CR18","doi-asserted-by":"publisher","unstructured":"Marshall, J., Ashe, K. M., Bangari, D., McEachern, K., Chuang, W. L., Pacheco, J., Copeland, D. P., Desnick, R. J., Shayman, J. A., Scheule, R. K., Cheng, S. H. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS One 5. https:\/\/doi.org\/10.1371\/journal.pone.0015033 (2010).","DOI":"10.1371\/journal.pone.0015033"},{"key":"93601_CR19","doi-asserted-by":"publisher","first-page":"6388","DOI":"10.1073\/pnas.96.11.6388","volume":"96","author":"M Jeyakumar","year":"1999","unstructured":"Jeyakumar, M. et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc. Natl. Acad. Sci. 96, 6388\u20136393 (1999).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"93601_CR20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ymgme.2008.02.005","volume":"94","author":"E Elliot-Smith","year":"2008","unstructured":"Elliot-Smith, E. et al. Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis. Mol. Genet. Metab. 94, 204\u2013211 (2008).","journal-title":"Mol. Genet. Metab."},{"key":"93601_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/(SICI)1097-4547(20000115)59:2<170::AID-JNR3>3.0.CO;2-G","volume":"59","author":"T Ezoe","year":"2000","unstructured":"Ezoe, T. et al. Biochemistry and neuropathology of mice doubly deficient in synthesis and degradation of galactosylceramide. J. Neurosci. Res. 59, 170\u2013178 (2000).","journal-title":"J. Neurosci. Res."},{"key":"93601_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/(SICI)1097-4547(20000115)59:2<179::AID-JNR4>3.0.CO;2-N","volume":"59","author":"T Ezoe","year":"2000","unstructured":"Ezoe, T. et al. Twitcher mice with only a single active galactosylceramide synthase gene exhibit clearly detectable but therapeutically minor phenotypic improvements. J. Neurosci. Res. 59, 179\u2013187 (2000).","journal-title":"J. Neurosci. Res."},{"key":"93601_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1471-4159.1984.tb02716.x","volume":"42","author":"KS Sundaram","year":"1984","unstructured":"Sundaram, K. S. & Lev, M. Inhibition of sphingolipid synthesis by cycloserine in vitro and in vivo. J. Neurochem. 42, 577\u2013581 (1984).","journal-title":"J. Neurochem."},{"key":"93601_CR24","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/jnr.23791","volume":"94","author":"SA Sands","year":"2016","unstructured":"Sands, S. A. & LeVine, S. M. Substrate reduction therapy for Krabbe\u2019s disease. J. Neurosci. Res. 94, 1261\u20131272 (2016).","journal-title":"J. Neurosci. Res."},{"key":"93601_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0304-3940(03)00633-5","volume":"347","author":"S Biswas","year":"2003","unstructured":"Biswas, S., Biesiada, H., Williams, T. D. & LeVine, S. M. Substrate reduction intervention by l-cycloserine in twitcher mice (globoid cell leukodystrophy) on a B6;CAST\/Ei background. Neurosci. Lett. 347, 33\u201336 (2003).","journal-title":"Neurosci. Lett."},{"key":"93601_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/(SICI)1097-4547(20000415)60:2<231::AID-JNR12>3.0.CO;2-E","volume":"60","author":"SM LeVine","year":"2000","unstructured":"LeVine, S. M., Pedchenko, T. V., Bronshteyn, I. G. & Pinson, D. M. L-cycloserine slows the clinical and pathological course in mice with globoid cell leukodystrophy (twitcher mice). J. Neurosci. Res. 60, 231\u2013236 (2000).","journal-title":"J. Neurosci. Res."},{"key":"93601_CR27","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1523\/JNEUROSCI.4199-14.2015","volume":"35","author":"JA Hawkins-Salsbury","year":"2015","unstructured":"Hawkins-Salsbury, J. A. et al. Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy. J. Neurosci. 35, 6495\u20136505 (2015).","journal-title":"J. Neurosci."},{"key":"93601_CR28","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1021\/jm050484f","volume":"49","author":"GG Muccioli","year":"2006","unstructured":"Muccioli, G. G. et al. Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: Characterization of new CB1 cannabinoid receptor inverse agonists\/antagonists. J. Med. Chem. 49, 872\u2013882 (2006).","journal-title":"J. Med. Chem."},{"key":"93601_CR29","unstructured":"Bing, W. WO2017214505A1\u2014Ceramide galactosyltransferase inhibitors for the treatment of disease (2017). (available at https:\/\/patents.google.com\/patent\/WO2017214505A1\/)."},{"key":"93601_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2013.04.001","volume":"106\u2013107","author":"BD Semple","year":"2013","unstructured":"Semple, B. D., Blomgren, K., Gimlin, K., Ferriero, D. M. & Noble-Haeusslein, J. L. Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across species. Prog. Neurobiol. 106\u2013107, 1\u201316 (2013).","journal-title":"Prog. Neurobiol."},{"key":"93601_CR31","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.celrep.2017.09.050","volume":"21","author":"RB Tripathi","year":"2017","unstructured":"Tripathi, R. B. et al. Remarkable stability of myelinating oligodendrocytes in mice. Cell Rep. 21, 316\u2013323 (2017).","journal-title":"Cell Rep."},{"key":"93601_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/0006-8993(80)90159-6","volume":"202","author":"T Kobayashi","year":"1980","unstructured":"Kobayashi, T., Yamanaka, T., Jacobs, J. M., Teixeira, F. & Suzuki, K. The twitcher mouse: An enzymatically authentic model of human globoid cell leukodystrophy (Krabbe disease). Brain Res. 202, 479\u2013483 (1980).","journal-title":"Brain Res."},{"key":"93601_CR33","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/brain\/103.3.695","volume":"103","author":"LW Duchen","year":"1980","unstructured":"Duchen, L. W., Eicher, E. M., Jacobs, J. M., Scaravilli, F. & Teixeira, F. Hereditary leucodystrophy in the mouse: The new mutant twitcher. Brain 103, 695\u2013710 (1980).","journal-title":"Brain"},{"key":"93601_CR34","doi-asserted-by":"publisher","first-page":"14821","DOI":"10.1073\/pnas.93.25.14821","volume":"93","author":"B Hess","year":"1996","unstructured":"Hess, B. et al. Phenotype of arylsulfatase A-deficient mice: Relationship to human metachromatic leukodystrophy. Proc. Natl. Acad. Sci. 93, 14821\u201314826 (1996).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"93601_CR35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0304-3940(99)00647-3","volume":"273","author":"R D\u2019Hooge","year":"1999","unstructured":"D\u2019Hooge, R. et al. Neuromotor alterations and cerebellar deficits in aged arylsulfatase A-deficient transgenic mice. Neurosci. Lett. 273, 93\u201396 (1999).","journal-title":"Neurosci. Lett."},{"key":"93601_CR36","doi-asserted-by":"publisher","first-page":"22623","DOI":"10.1074\/jbc.C000200200","volume":"275","author":"H Fujimoto","year":"2000","unstructured":"Fujimoto, H. et al. Requirement of seminolipid in spermatogenesis revealed by UDP-galactose: Ceramide galactosyltransferase-deficient mice. J. Biol. Chem. 275, 22623\u201322626 (2000).","journal-title":"J. Biol. Chem."},{"key":"93601_CR37","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1046\/j.1471-4159.1995.65052267.x","volume":"65","author":"N Schaeren-Wiemers","year":"1995","unstructured":"Schaeren-Wiemers, N., van der Bijl, P. & Schwab, M. E. The UDP-galactose:ceramide galactosyltransferase: Expression pattern in oligodendrocytes and Schwann cells during myelination and substrate preference for hydroxyceramide. J. Neurochem. 65, 2267\u20132278 (1995).","journal-title":"J. Neurochem."},{"key":"93601_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/cts.12424","volume":"9","author":"K Kanhai","year":"2016","unstructured":"Kanhai, K. et al. Quantifying beta-galactosylceramide kinetics in cerebrospinal fluid of healthy subjects using deuterium labeling. Clin. Transl. Sci. 9, 321\u2013327 (2016).","journal-title":"Clin. Transl. Sci."},{"key":"93601_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0092-8674(00)80093-8","volume":"86","author":"T Coetzee","year":"1996","unstructured":"Coetzee, T. et al. Myelination in the absence of galactocerebroside and sulfatide: Normal structure with abnormal function and regional instability. Cell 86, 209\u2013219 (1996).","journal-title":"Cell"},{"key":"93601_CR40","doi-asserted-by":"publisher","first-page":"30022","DOI":"10.1074\/jbc.M111.261206","volume":"286","author":"O Ben-David","year":"2011","unstructured":"Ben-David, O. et al. Encephalopathy caused by ablation of very long acyl chain ceramide synthesis may be largely due to reduced galactosylceramide levels. J. Biol. Chem. 286, 30022\u201330033 (2011).","journal-title":"J. Biol. Chem."},{"key":"93601_CR41","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1523\/JNEUROSCI.18-05-01642.1998","volume":"18","author":"JL Dupree","year":"1998","unstructured":"Dupree, J. L., Coetzee, T., Blight, A., Suzuki, K. & Popko, B. Myelin galactolipids are essential for proper node of Ranvier formation in the CNS. J. Neurosci. 18, 1642\u20131649 (1998).","journal-title":"J. Neurosci."},{"key":"93601_CR42","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","volume":"388","author":"M Sessa","year":"2016","unstructured":"Sessa, M. et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: An ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial. Lancet 388, 476\u2013487 (2016).","journal-title":"Lancet"},{"key":"93601_CR43","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ymthe.2005.04.019","volume":"12","author":"D Lin","year":"2005","unstructured":"Lin, D. et al. AAV2\/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2. Mol. Ther. 12, 422\u2013430 (2005).","journal-title":"Mol. Ther."},{"key":"93601_CR44","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1046\/j.1471-4159.1996.66031118.x","volume":"66","author":"N Sakai","year":"1996","unstructured":"Sakai, N. et al. Molecular cloning and expression of cDNA for murine galactocerebrosidase and mutation analysis of the twitcher mouse, a model of Krabbe\u2019s disease. J. Neurochem. 66, 1118\u20131124 (1996).","journal-title":"J. Neurochem."},{"key":"93601_CR45","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1002\/bmc.4235","volume":"32","author":"R Sidhu","year":"2018","unstructured":"Sidhu, R. et al. A HILIC-MS\/MS method for simultaneous quantification of the lysosomal disease markers galactosylsphingosine and glucosylsphingosine in mouse serum. Biomed. Chromatogr. 32, 4235 (2018).","journal-title":"Biomed. Chromatogr."},{"key":"93601_CR46","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1194\/jlr.M021261","volume":"53","author":"SD Larsen","year":"2012","unstructured":"Larsen, S. D. et al. Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J. Lipid Res. 53, 282\u2013291 (2012).","journal-title":"J. Lipid Res."},{"key":"93601_CR47","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3343\/alm.2015.35.1.165","volume":"35","author":"M Han","year":"2015","unstructured":"Han, M. et al. Ultra-performance liquid chromatography-tandem mass spectrometry measurement of leukocyte arylsulfatase A activity using a natural substrate. Ann. Lab. Med. 35, 165\u2013168 (2015).","journal-title":"Ann. Lab. Med."},{"key":"93601_CR48","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1084\/jem.20172048","volume":"215","author":"Q Cao","year":"2018","unstructured":"Cao, Q. et al. Inhibition of UGT8 suppresses basal-like breast cancer progression by attenuating sulfatide\u2013\u03b1V\u03b25 axis. J. Exp. Med. 215, 1679\u20131692 (2018).","journal-title":"J. Exp. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93601-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93601-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93601-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T06:31:25Z","timestamp":1670049085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93601-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["93601"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-93601-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"assertion":[{"value":"26 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MCB, BW, SaC, SuC, YX, KW, YF, AG, BKY, ML, QC, JCW, YS, SB, and BEC are current or former employees of BioMarin which has filed patent applications on the CGT inhibitors, US Patent WO 2017\/214505 Al and WO\/2020\/028221. All other authors declare they have no competing interests<b>.<\/b>","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14486"}}